ArticleJournal of Inonu Liver Transplantation Institute2025
A Network Phenotyping Strategy approach in a Turkish HCC Dataset and Comparison of Patients Selected for Transplant and those who were not.
Article in Journal of Inonu Liver Transplantation Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamic Changes in Serum AFP, Albumin and ALBI after Radioembolization in Patients with Unresectable Hepatocellular Carcinoma with High or Low Alpha-Fetoprotein Levels.Japanese journal of gastroenterology and hepatology · 2026Article
- Prognostic Factor and Serum Biomarker Changes in Non-Surgical Hepatocellular Carcinoma Patients Treated with Radioembolization.Japanese journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objectives: A Network Phenotyping Strategy (NPS) was recently created to stage hepatocellular carcinoma (HCC) from an Italian dataset into 25 discrete phenotypes sT, Methods: To use NPS methodology on an ethnically different, Turkish HCC cohort that had, in addition, been stratified according to patients selected for liver transplantation or not. Results: The Turkish patients had only a smaller subset of 16 out of the 25 HCC phenotypes of the Italian patients. HCC progression through phenotypes, which are exclusive to the Italian population, is a dominantly tumor biology-driven process, occurring within a constant extent of liver microenvironment damage. In contrast, in phenotypes shared by the minority of Italian patients and the majority of Turkish patients, the HCC progresses by a more complex disease burden generating mechanism, consisting of simultaneous tumor biology-driven damage, accompanied by advancing liver microenvironmental impairment.NPS objective stratification of a "real world clinical practice" patient cohort into subpopulations with identical HCC clinical phases enabled the simulation of clinician-dependent selection for liver transplantation or not in this cohort, using specific baseline variables. A clearer understanding of HCC biology has allowed us to identify differing biological phenotypes. The predominant 12T phenotype was examined in detail and combined with surgical knowledge obtained retrospectively as to the difference between transplanted and non-transplanted patients to then derive models that may be useful for biology-dependent surgical decision support in future patients. Conclusion: Only a subset of all HCC phenotypes appeared in the Turkish cohort and may be explained by the non-screened patients having HCC as a secondary problem, and is primarily driven by the liver microenvironment, in contrast to Italy, where HCC develops (predominantly) in healthier livers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.